Drug intelligence / Profile preview

G2306

Development stage: Preclinical
Lead developer: BCWorld Pharma
Modality: Small Molecules
Administration: Oral

Overview

G2306 is a small molecule therapeutic candidate being developed by BCWorld Pharma for the treatment of hyperlipidemia. The drug is formulated as an orally disintegrating tablet (ODT), utilizing the company's specialized drug delivery system (DDS) technologies to improve patient compliance and administration convenience by allowing the tablet to dissolve rapidly in the mouth without the need for water. As of 2024, G2306 is in the preclinical stage of development.

Beyond the preview

Go deeper on G2306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G2306.

Explore the full profile